YORVIPATH launching in U.S. with product availability expected mid-January 2025; ex-U.S. YORVIPATH revenue of €8.5 million in ...

Ascendis Pharma’s (ASND) Palopegteriparatide is a once-daily PTH replacement therapy approved by the FDA and EMA and branded as Yorvipath. It's the only approved drug for HP, although it's not yet ...

Metsera has brought in over $500m in funding in just seven months as it looks to enter the competitive weight loss arena.

The race moves to the November general election for the four-year term of District 5 Cape Coral City Council representative, featuring Joseph Kilraine and Charlie Pease who made it through the ...

Ascendis Pharma (ASND) has released an update. Ascendis Pharma A/S has structured its capital to enable significant growth opportunities, with ...

Ascendis Pharma (ASND) is scheduled to announce Q3 earnings results on Thursday, November 14th, after market close. The ...

In 2022, the calcium supplements category accounted for 38.29% of market revenue. Amolyt Pharma revealed an oral presentation ...

Adults with hypoparathyroidism treated with TransCon PTH in the phase 3 PaTHway open-label trial extension demonstrated ...

In a report released today, Vikram Purohit from Morgan Stanley maintained a Hold rating on Ascendis Pharma (ASND – Research Report), with a price target of $167.00. The company’s shares closed last ...

GET MORE AI-GENERATED SIGNALS: November 10, 2024, 17:44 pm ET, BY Jesse F.- Contributor| Editor: Thomas H. Kee Jr. ( Follow ...

Royalty Pharma's Q3 results show growth driven by strong portfolio performance and acquisitions. See why we recommend a buy ...